635 A novel site-directed chemical conjugation technology confers antitumor activity via native Fc receptor to plasma immunoglobulin by attaching tumor binders
Vidal, Christian, Cukan, Michael, Varma, Rajat, Iben, Lawrence, Berbasova, Tanya, Vaill, Ada, Bunin, Anna, Rossi, Ann Marie, Trinh, David, McGrath, Katy, Alvarez, Enrique, Welsch, Matthew, Rastelli, Luca
Published in Journal for immunotherapy of cancer (01.11.2020)
Published in Journal for immunotherapy of cancer (01.11.2020)
Get full text
Journal Article
A Novel Class of Bifunctional Immunotherapeutic That Exploits a Universal Antibody Binding Terminus (uABT) to Recruit Endogenous Antibodies to Cell Expressing CD38 Demonstrate In Vivo efficacy in Three Distinct Animal Models
Bunin, Anna, McGrath, Katy, Rossi, Ann Marie, Welsch, Matthew, Vidal, Christian, Trinh, David, Spiegel, David, Rastelli, Luca, Alvarez, Enrique
Published in Blood (13.11.2019)
Published in Blood (13.11.2019)
Get full text
Journal Article
KPMW135, a Biosuperior CD3 Bispecific Version of Rituximab Created By a Novel Chemical Conjugation Technology Demonstrates Increased Anti-Tumor Activity By Adding T Cell-Mediated Cytotoxicity Activity to the Existing Mechanisms of Rituximab
Vidal, Christian, Cukan, Michael, Vaill, Ada, Bunin, Anna, Rossi, Ann Marie, Iben, Lawrence, Trinh, David, McGrath, Katy, Berbasova, Tanya, Romee, Rizwan, Alvarez, Enrique, Rastelli, Luca, Welsch, Matthew
Published in Blood (05.11.2020)
Published in Blood (05.11.2020)
Get full text
Journal Article